Posted by Solana Pinilla – 08/04/2024
WHO: “My health, my right” campaign
In an increasingly interconnected and technologically advanced world, health emerges as a fundamental pillar that supports not only individual life, but also the collective well-being of our societies. The World Health Organization (WHO), in its role as guide in the global health landscape, annually reminds us of the importance of reflecting and acting towards the continuous improvement of health systems through the commemoration of the Day World Health. This year 2024, under the motto “My Health, My Right”, a deeply human messageis revealed, including concepts such as access to quality health service, access to drinking water and sanitation, living with clean air, developing in a safe and healthy environment, have quality housing and have a varied diet. All these elements, together, ensure comprehensive well-being, which contributes to people’s health. This slogan not only resonates in the ears of those committed to the advancement of biotechnology and medicine, but also invites the entire global community to reflect on how innovations in these fields can be a vehicle to guarantee and amplify said right. Biotechnology, with its unique capacity to innovate therapies, diagnostics and healthcare solutions, plays a crucial role in realizing this right. However, it faces the constant challenge of occupying a central role in the political and social agenda of different governments.
Mikrobiomik focuses on improving people's quality of life
On the occasion of “World Health Day”, from Mikrobiomik, we want to emphasize its importance. Health is more than the absence of disease; It is the integral well-being of the human being. Our commitment goes beyond research and development; It is rooted in the continuous improvement of the quality of life of people suffering from various pathologies. With a highly committed team specialized in the biotechnology sector, we are dedicated to the development of izado en el sector de la biotecnología, estamos dedicados al desarrollo de MBK-01, a biological medicine based on the intestinal microbiota, which represents a promising advance in the treatment of Clostridioides difficileinfections. This bacteria, responsible for serious intestinal infections, represents a challenge in the field of health, especially for those patients who do not respond to conventional therapies, and reoccur from the infection, and this bacteria can become a threat to the life of the people. At Mikrobiomik, we work every day with the conviction that it is possible to make a significant difference in people’s lives through biotechnology, always with a spirit of compassion, ethics and excellence. Because at the end of the day, what drives us is the possibility of saving lives and contributing to a healthier world. This is where our work gains value, offering a light of hope through the compassionate use , program, which is already underway for all hospitals in Spain, providing a therapeutic alternative to patients affected by the Clostridioides difficile bacteria.
Compassionate Use Program in Spain
The compassionate use program in Spain is a regulatory framework that allows access to medications that have not yet been authorized, in cases where patients with serious or life- threatening diseases do not have therapeutic alternatives available. This program is based on the understanding that, in certain circumstances, the potential benefit of an experimental treatment outweighs the risks associated with its use prior to full evaluation and approval by regulatory authorities.The legislation governing compassionate use in Spain is mainly found in Royal Decree 1015/2009. This decree establishes the criteria and procedure for access to treatments not yet authorized, ensuring that this access is carried out in a controlled manner and based on available scientific evidence. The process requires a request from the treating physician, who must justify the absence of adequate therapeutic alternatives and obtain the informed consent of the patient or their legal representatives. The Spanish Agency for Medicines and Health Products(AEMPS) is responsible for supervising and authorizing compassionate use requests. This entity ensures that patients access these treatments safely and with adequate follow-up, evaluating information on the effectiveness and safety of the medication. In this way, the compassionate use program stands as a vital instrument to offer hope and therapeutic options to patients in critical conditions, within a legal framework that protects their well-being and rights. The implementation of the compassionate use program for MBK-01 in Spain has managed to bring hope to patients facing significant health challenges, particularly those diagnosed with Clostridioides difficile, offering a therapeutic alternative that makes a difference in their lives. We are proud not only to lead the field of microbiota, but also to ensure that our solutions are accessible to all those who need them, which so far have benefited 45 patients from different hospitals in Spain, they are concrete and real cases, benefiting from this program.At Mikrobiomik, each achievement, each advance brings us a little closer to our ultimate goal: saving lives and contributing to the global right to health.
